Recent investigations have focused on the convergence of GLP|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic neurotransmission. While GIP activators are increasingly employed for treating type 2 diabetes mellitus, their potential impacts on reinforcement circu